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INTRODUCTION
Less than 5% of patients with metastatic gestational tropho­
blastic neoplasia (GTN) have initial involvement of the gas­
tro  in  tes  tinal tract [1]. Also, chemotherapy is the primary 
treat  ment for metastatic GTN. Although the role of surgery in 
metastatic choriocarcinoma has diminished, local resection 
of metastases still seems to play a role in a small subset of pa­
tients [2]. Here, we present a case of chemo­resistant chorio­
carcinoma, metastatic to the colon, which was salvaged by 
surgery.
CASE REPORT
In September 2000, a 48­year­old woman, gravid 4 para 2, 
presented with acute abdominal pain and hypovolemic shock. 
Her initial blood pressure was 82/56 mm Hg, pulse rate was 
112 beats/minute, and initial hemoglobin was 7.6 g/dL. She 
underwent an emergency laparotomy, which showed uterine 
perforation and severe intractable hemorrhage. But there was 
no seeding nodules or mass, except for the uterus. Total hys­
terectomy and bilateral salpingo­oophorectomy showed an 
invasive choriocarcinoma. The postoperative human chorionic 
gonadotropin (hCG) level was 34 mIU/mL and was normalized 
during the four cycles of methotrexate and folic acid rescue 
(MTX­CF) after the operation (Table 1).
In January 2002, the hCG level was elevated (64.9 mIU/mL) 
and abdomen­pelvis magnetic resonance imaging (MRI) 
showed a soft tissue nodular mass adherent to the inferopos­
terior wall of the sigmoid colon. There was no evidence of 
metastases in other sites on the abdomen­pelvis MRI, chest 
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The role of surgery in the treatment of patients with metastatic choriocarcinoma has diminished. We present a case of chemo­
resistant metastatic choriocarcinoma salvaged by surgery. A 48­year­old patient presented with uterine perforation and severe 
intractable hemorrhage, and histological examination revealed a choriocarcinoma. After 6 years of disease­free state, recurrence 
occurred in the rectosigmoid colon. Seven cycles of EMACO chemotherapy was administered, and the human chorionic 
gonadotropin level was normalized. Three months after the chemotherapy, the rectosigmoid colon metastasis progressed. Low 
anterior resection with lymphadenectomy up to the level of the inferior mesenteric artery was conducted. After the operation, 
the human chorionic gonadotropin level decreased to within the normal range. There has been no evidence of disease for 13 
months since the operation. Local resection of metastases seems to play a significant role in curing the disease in a small subset 
of patients.
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computed tomography (CT), and brain CT. Four cycles of 
combination chemotherapy with EMACO (weekly alternating 
etoposide, methotrexate, actinomycin D/vincristine, and cy­
clophosphamide) were administered, and the hCG level was 
normalized following the 2nd cycle. Since 2002, she had been 
lost for follow­up.
In August 2008, she was hospitalized again for rectal bleed­
ing. Her hemoglobin value was 4.7 g/dL, and the hCG level 
was 154,380 mIU/mL. Diffuse irregular wall thickening of the 
rec  tosigmoid colon with regional lymphadenopathy was 
iden  tified in the abdomen­pelvis MRI (Fig. 1A). Sigmoidoscopy 
dis  played a lobulating metastatic choriocarcinoma proven 
by biopsy (Fig. 1B). In the chest CT, pleural thickening with 
minimal amount of effusion was seen, which was suggestive 
of metastases. Under the impression of recurrent choriocarci­
noma, EMACO chemotherapy had been administered seven 
times. The hCG level normalized following 4th cycle of che­
motherapy.
Three months after the chemotherapy, the hCG level had again 
risen up to 657 mIU/mL. The abdomen­pelvis CT sho  wed in­
ter  val progression of the recurrent mass. The positron emis­
sion tomography (PET) scan revealed increased fludeoxyglu­
cose uptake (SUVmax=9.9) in the rectosigmoid colon (Fig. 1C). 
Sigmoidoscopic findings showed stenosis and a protruding 
mass 14 cm above the anal verge junction. 
A secondary cytoreductive surgery for chemo­resistant cho­
rio  carcinoma was performed and a huge ulcerative mass ap­
p  ea    red at the rectosigmoid junction. Low anterior resection 
with lymphadenectomy up to the level of the inferior me  sen­
te  ric artery was performed with no residual mass. The histo­
lo  gical examination confirmed metastatic chorio  carcinoma 
in  volving from the mucosa to the subserosa of the sigmoid 
colon (Fig. 1D). 
After the operation, the hCG level dropped from 6,298 mIU/
mL to 2.8 mIU/mL. The patients refused further chemothera­
py. However, there has been no evidence of recurrence for 13 
months since the operation.
DISCUSSION
We have described a rare case of metastatic GTN responsive 
to surgery. In this case, the chemo­resistant GTN was treated 
with low anterior resection. Moreover, the patient reached 
com  plete remission shortly after removing the colon meta­
stases. 
The prognosis of choriocarcinoma has been substantially im­
proved by the introduction of chemotherapeutic agents. GTN 
is extremely responsive to chemotherapy, even in its meta­
static forms [3]. Therefore, the role of surgery in the treatment 
of patients with metastatic choriocarcinoma has diminished.
The role of surgery in the treatment of metastatic chorio­
carcinoma has long been debated. In general, resection of 
distant metastasis is unlikely to succeed if there is evidence of 
disseminated disease resistant to chemotherapy. In the 1960s, 
Lewis and his associates documented that the common indi­
cations for surgery in GTN were the need for controlling hem­
orrhage, removing residual disease when resistant to chemo­
therapy, relieving urologic obstruction, and treating infection 
[3,4]. Also, local resection of metastases still seems to play a 
significant role even in curing the disease in a small subset of 
patients.
Choriocarcinoma is characterized by the rapid invasion of 
surrounding tissue and early hematogenous metastases [5]. 
Common sites of metastases outside the pelvis are the lung, 
liver, and kidney [5]. Less than 5% of cases of metastatic GTN 
involve the gastrointestinal tract [1]. Although risk factor of 
colonic metastases is not known, it is assumed that previous 
Table 1. Chemotherapy protocols given to the patient
Date Time 
(mo)
β-hCG 
(mIU/mL)
Chemotherapy 
regimen Events
Sep-2000 0 NA MTX-CF* TAH and BSO
Sep-2000 1 NA
Nov-2000 2 NA
Dec-2000 3 NA
Jan-2001 4 NA
Feb-2002 17 55.5 EMACO
†
Mar-2002 18 4.7
Apr-2002 19 6.3
May-2002 20 0.1
Aug-2008 34 270,000 EMACO
†
Aug-2008 35 15,500
Nov-2008 36 164.1
Oct-2008 37 29.3
Oct-2008 38 7.6
Nov-2008 39 5.6
Nov-2008 40 2.9
Feb-2009 52 6,026 EMACO
†
Mar-2009 53 33.9 LAR
Nov-2009 59 1.4 NED
hCG, human chorionic gonadotropin; NA, not available; MTX-CF, me-
tho  trexate and folic acid rescue; TAH, total abdominal hysterectomy; 
BSO, bilateral salpingo-oophorectomy; LAR, low anterior resection; 
NED, no evidence of disease. 
*MTX-CF, methotrexate 1.0 mg/kg+CF 0.1 mg/kg. 
†Etoposide 
100 mg/m
2+methotrexate 300 mg/m
2+actinomycin D 0.5 mg+ 
cyclophosphamide 600 mg/m
2+vincristine 1 mg/m
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uterine perforation is associated with colonic recurrence [3]. 
It is not known whether intestinal metastases would place 
patients at a higher risk of treatment failure. However, bowel 
resection may be beneficial in selected patients with intestinal 
metastases resistant to chemotherapy.
The treatment of chemo­resistant GTN should be individual­
ized. All patients with high­risk should be treated with inten­
sive combination chemotherapy and the selective use of radi­
ation therapy and surgery. Recently, several authors reported 
favorable results with salvage surgery for chemotherapy­
resistant GTN [6]. Hysterectomy may be necessary to control 
uterine hemorrhage or sepsis, or to resect resistant disease [6]. 
Thoracotomy may be performed to excise a persistent viable 
tumor despite intensive chemotherapy [7]. Hepatic resection 
may be required to manage bleeding metastases although 
embolization has also been utilized in this setting [5]. Crani­
otomy may be necessary to provide acute decompression or 
to control bleeding, in addition to its role in the primary resec­
tion of solitary metastatic disease [8]. 
Feng et al. [9] have suggested that age older than 35 years, 
antecedent non­molar pregnancy, distant metastasis outside 
of the lungs and uterus, and a preoperative serum β­hCG 
level greater than 10 IU/L are important clinical predictors 
of treatment failure, which will require following surgery. An 
extensive metastatic survey should be undertaken to exclude 
other sites of persistent tumor. A PET scan may be useful to 
identify occult sites of viable tumor [10].  
In conclusion, although combination chemotherapy is the 
main treatment used in patients with high­risk GTN, surgical 
intervention may occasionally be required. In this case, sur­
gery was effective for the cure of chemo­refractory choriocar­
cinoma, metastatic to the colon. 
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